Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
March 03, 2017 07:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases...
Vericel to Present at Multiple Upcoming Investor Conferences
February 27, 2017 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases...
Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
February 21, 2017 07:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases...
Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
February 01, 2017 07:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases...
Vericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $20 Million Offering of Common Stock
December 21, 2016 16:05 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases...
Vericel Corporation Prices $17 Million Public Offering of Common Stock
December 16, 2016 09:14 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases...
Vericel Corporation Announces Proposed Public Offering of Common Stock
December 15, 2016 18:11 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases...
FDA Approves MACI for the Treatment of Symptomatic Cartilage Defects of the Knee in Adults
December 14, 2016 07:09 ET
|
Vericel Corporation
First Tissue-Engineered Autologous Cellularized Scaffold Product Approved by the FDA Conference Call Today at 9:00am Eastern Standard Time CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) --...
Vericel to Present at 28th Annual Piper Jaffray Healthcare Conference
November 22, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases...
Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel’s Positive Phase 2b ixCELL‑DCM Clinical Trial of Ixmyelocel-T
November 14, 2016 14:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and...